IBD ahead 2010 answering important questions in Crohns disease treatment;IBD ahead 2010 Antworten auf zehn zentrale Fragen in der aktuellen Therapie des Morbus Crohn

Zeitschrift fur Gastroenterologie

Volumn 49, Issue 9, 2011, Pages 1246-1254

  Schmidt, C ^a   Dignass, A ^b   Hartmann, F ^c   Huppe D ^d   Kruis, W ^e   Layer, P ^f   Luers A ^g   Stallmach, A ^a   Teich, N ^h   Sturm, A ⁱ  

^a Abteilung für Gastroenterologie Hepatologie und Infektiologie   (Germany)

^b AGAPLESION MARKUS KRANKENHAUS   (Germany)

^c Elisabethen Krankenhaus   (Germany)

^d Gastroenterologische Gemeinschaftspraxis   (Germany)

^e Evangelisches Krankenhaus Kalk   (Germany)

^f ISRAELITISCHES KRANKENHAUS   (Germany)

^g UNIVERSITY HOSPITAL MARBURG   (Germany)

^h Internistische Gemeinschaftspraxis Für Verdauungs Und Stoffwechselkrankheiten Leipzig Und Schkeuditz   (Germany)

ⁱ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

chronic inflammarory bowel disease; Crohns disease; intestinal complications

Indexed keywords

CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ARTICLE; CLINICAL PRACTICE; CROHN DISEASE; HUMAN; INFECTIOUS COMPLICATION; MEDICAL LITERATURE; MEDICAL RESEARCH; NEOPLASM; PATIENT MONITORING; PATIENT SAFETY; RISK ASSESSMENT; TREATMENT DURATION; TREATMENT FAILURE;

ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL; CROHN DISEASE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IRRITABLE BOWEL SYNDROME; TREATMENT FAILURE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80052404654     PISSN: 00442771     EISSN: 14397803     Source Type: Journal    
DOI: 10.1055/s-0031-1273416     Document Type: Article

References (54)

1. Benchimol E l, Seow C H., Steinhart A H. et al. Traditional corticosteroids for induction of remission in Crohns disease. Cochrane Database Syst Rev 2008 2 CD006792
2. Hoffmann J C., Preiss J C., Autschbach F et al. Clinical practice guideline on diagnosis and treatment of Crohns disease. Z Gastroenterol 2008 46 1094-1146
3. Yang Y X., Lichtenstein G R. Corticosteroids in Crohns disease. Am J Gastroenterol 2002 97 803-823
4. Greenberg G R., Feagan B G., Martin F et al. Oral budesonide for active Crohns disease. Cannadial Inflammatory Bowel Disease Study Group. N Engl J Med 1994 331 836-841
5. Seow C H., Benchimol E I., Griffiths A M. et al. Budesonide for induction of remission in Crohns disease. Cochrane Database Syst Rev 2008 3 CD000296
6. Lichtenstein G R., Abreu M T., Cohen R et al. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators and infliximab in inflammatory bowel disease. Gastroenterology 2006 130 940-987 (Pubitemid 43374543)
7. Munkholm P, Langholz E, Davidsen M et al. Frequency of glucocorticoid resistance and dependency in Crohns disease. Gut 1994 35 360-362
8. Steinhart A H., Ewe K, Griffiths K M. et al. Corticosteroids for maintenance of remission in Crohns disease. Cochrane Database Syst Rev 2003 (4) CD000301
9. Benchimol E I., Seow C H., Otley A R. et al. Budesonide for maintenance of remission in Crohns disease. Cochrane Database Syst Rev 2009 1 CD002913
10. Bernstein C N., Leslie W D., Leboff M S. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 2003 124 795-841 (Pubitemid 36268496)
11. Dignass A, Van Assche G, Lindsay J O. et al. The second European evidence-based Consensus on the diagnosis and management of Crohns disease: current management. JCrohns Colitis 2010 4 28-62
12. Prefontaine E, Sutherland L R., Macdonald J K. et al. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohns disease. Cochrane Database Syst Rev 2009 1 CD000067
13. Peyrin-Biroulet L, Deltenre P, Ardizzone S et al. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohns disease: a meta-analysis. Am J Gastroenterol 2009 104 2089-2096
14. Nielsen O H., Rogler G, Hahnloser D et al. Diagnosis and management of fistulizing Crohns disease. Nat Clin Pract Gastroenterol Hepatol 2006 6 92-106
15. Beaugerie L, Seksik P, Nion-Larmurier I et al. Predictors of Crohns disease. Gastroenterology 2006 130 650-656
16. Allez M, Lemann M, Bonnet J et al. Long term outcome of patients with active Crohns disease exhibiting extensive and deep ulcerations at colonoscopy. Am J Gastroenterol 2002 97 947-953 (Pubitemid 34408253)
17. Fraser A G., Orchard T R., Jewell D P. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002 50 485-489 (Pubitemid 34638866)
18. Hindorf U, Johansson M, Eriksson A et al. Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease. Aliment Pharmacol Ther 2009 29 654-661
19. Feagan B G., Rochon J, Fedorak R N. et al. Methotrexate for the treatment of Crohns disease. The North American Crohns Study Group Investigators. N Engl J Med 1995 Feb 2 Feb 1995 332 (5) 292-297
20. Lémann M, Mary J Y., Colombel J F. et al. A randomized, double-blind, controlled withdrawal trial in Crohns disease patients in long-term remission on azathioprine. Gastroenterology 2005 128 1812-1818 (Pubitemid 40824692)
21. Holtmann M H., Krummenauer F, Claas C et al. Long-term effectiveness of azathioprine in IBD beyond 4 years: a European multicenter study in 1176 patients. Dig Dis Sci 2006 51 1516-1524 (Pubitemid 44379292)
22. Patel V, Macdonald J K., McDonald J W. et al. Methotrexate for maintenance of remission in Crohns disease. Cochrane Database Syst Rev 2009 4 CD006884
23. Thia K T., Sandborn W J., Lewis J D. et al. Defining the optimal response criteria for the Crohns disease activity index for induction studies in patients with mildly to moderately active Crohns disease. American Journal of Gastroenterology 2008 103 3123-3131
24. Langhorst J, Elsenbruch S, Koelzer J et al. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. American Journal of Gastroenterology 2008 103 162-169
25. Canani R B., Terrin G, Rapacciuolo L et al. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig Liver Dis 2008 40 547-553
26. Afif W, Loftus E V., Faubion W A. et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010 105 1133-1139
27. Daperno M Jr, DHaens G, Van Assche G et al. Development and validation of a new, simplified endoscopic activity score for Crohns disease: the SES-CD. Gastrointestinal Endoscopy 2004 60 505-512 (Pubitemid 39311530)
28. Baert F, Moortgat L, Van Assche G et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohns disease. Gastroenterology 2010 138 463-468
29. Pineton de Chambrun G, Peyrin-Biroulet L, Lémann M et al. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol 2010 7 15-29
30. Colombel J F., Sandborn W J., Reinisch W et al. Infliximab, azathioprine, or combination therapy for Crohns disease. N Engl J Med 2010 362 1383-1395
31. Toruner M, Loftus E V., Harmsen W S. et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008 134 929-936 (Pubitemid 351451967)
32. Johnson F R., Ozdemir S Jr, Mansfield C et al. Crohns disease patients risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology 2007 133 769-779 (Pubitemid 47374126)
33. Rutgeerts P, Diamond R H., Bala M et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohns disease. Gastrointest Endosc 2006 63 433-442 (Pubitemid 43261469)
34. Van Assche G, Magdelaine-Beuzelin C, DHaens G et al. Withdrawal of immunosuppression in Crohns disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008 134 1861-1868 (Pubitemid 351790744)
35. Beaugerie L, Brousse N, Bouvier A M. et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009 374 1617-1625
36. Hanauer S, Feagan B, Lichtenstein G et al. Maintenance infliximab for Crohns disease: the ACCENT I randomised trial. Lancet 2002 359 1541-1549 (Pubitemid 34621118)
37. Colombel J F., Sandborn W, Rutgeerts P et al. Adalimumab for maintenance of clinical response and remission in patients with Crohns disease: The CHARM Trial. Gastroenterology 2007 132 52-65 (Pubitemid 46108762)
38. Sands B, Anderson F, Bernstein C et al. Infliximab maintenance therapy for fistulizing Crohns disease. N Engl J Med 2004 350 876-885 (Pubitemid 38252535)
39. Lemann M, Mary J Y., Duclos B et al. Infliximab plus azathioprine for steroid-dependent Crohns disease patients: a randomized placebo-controlled trial. Gastroenterology 2006 130 1054-1061
40. Reinshagen M, Schutz E, Armstrong V W. et al. 6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active Crohn disease: results from a randomized, controlled, open trial. Clin Chem 2007 53 1306-1314 (Pubitemid 47020987)
41. Neurath M F., Kiesslich R, Teichgräber U et al. 6-thioguanosine diphosphate and triphosphate levels in red blood cells and response to azathioprine therapy in Crohns disease. Clin Gastroenterol Hepatol Oct 2005 3 (10) 1007-1014 (Pubitemid 41415749)
42. Faubion W, Loftus E, Harmsen W et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001 121 255-260 (Pubitemid 32729372)
43. Vermiere S, Noman M, Van Assche G et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohns disease. Gut 2007 56 1226-1231 (Pubitemid 47300423)
44. Sandborn W, Rutgeerts P, Enns R et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007 146 829-838 (Pubitemid 351650483)
45. DHaens G, Rutgeerts P. Immunosuppression-associated lymphoma in IBD. Lancet 2009 374 1572-1573
46. Bernstein C N., Blanchard J F., Kliewer E et al. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 2001 91 854-862 (Pubitemid 32173312)
47. Shale M, Kanfer E, Panaccione R et al. Hepatosplenic T cell lymphoma in inflammatory bowel disease. Gut 2008 57 1639-1641
48. Long M D., Herfarth H H., Pipkin C et al. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2010 8 268-274
49. Siegel C A., Marden S M., Persing S M. et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohns disease: a meta-analysis. Clin Gastroenterol Hepatol 2009 7 874-881
50. Lewis J D., Schwartz J S., Lichtenstein G R. Azathioprine for maintenance of remission in Crohns disease: benefits outweigh the risk of lymphoma. Gastroenterology Jun 2000 118 1018-1024 (Pubitemid 30346977)
51. Connell W R., Kamm M A., Ritchie J K. et al. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993 34 1081-1085 (Pubitemid 23245359)
52. Vernier-Massouille G, Cosnes J, Lemann M et al. Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine. Gut 2007 56 1404-1409 (Pubitemid 47517834)
53. Teml A, Schaeffeler E, Herrlinger K R. et al. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing. Clin Pharmacokinet 2007 46 187-208 (Pubitemid 46425646)
54. Colombel J F., Ferrari N, Debuysere H et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohns disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000 118 1025-1030 (Pubitemid 30346978)